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SHORT COMMUNICATION

Wilson's Disease: Experience at a Tertiary Care Hospital
Om Parkash1, Adil Ayub2, Wasim Jafri1, Syed Hasnain Alishah1 and Saeed Hamid1

ABSTRACT

Wilson's disease (WD) is a rare autosomal recessive disorder of copper metabolism. Data regarding WD is not available
from Pakistan. A cross-sectional study was conducted at The Aga Khan University Hospital, Karachi, and all patients
admitted with primary and secondary diagnosis of Wilson's disease were added. A total of 47 patients were seen; 68%
(n = 32) were male. The mean age was 26.6 ± 9.97 years. Most of the patients presented with hepatic, (n = 22, 46.8%),
neurological, (n = 17, 36.2%) and psychiatric (n = 8, 17%) symptoms. Mean ceruloplasmin level was 0.17 ± 0.13 g/dl; it
was < 0.25 g/dl in 39 (86.6%) patients. Serum copper (Cu) was reduced in 32 (68.1%) patients and 24-hr-urinary Cu was
raised in 22 (47.6%) patients. Slit lamp examination for Kayser-Fleischer (KF) rings was done on 15 (31.9%) patients and
9 (60%) of them had KF rings. Mean serum aspartate transaminase (AST) / alanine transaminases (ALT) ratio was 1.92
and median alkaline phosphatase / total bilirubin ratio was 79.30 (IQR 35.05; 166.50).
Key Words: Wilson’s disease. Kayser-Fleischer (KF) ring. Serum copper.

Wilson's disease (WD) is a rare autosomal recessive
disorder of copper metabolism, caused by decreased
biliary copper excretion and deposition in liver, brain,
kidneys and skeletal system. The patients present with a
variety of clinical symptoms, the most common being
liver disease, neurological and psychiatric disturbances.1,2 The diagnosis of WD is difficult because of
lack of specific and sensitive tests for WD. Due to
relative rarity of WD and lack of awareness among the
physicians, this disease is not diagnosed early, at least
in our country. Therefore, majority of patients present
late with either decompensated liver disease or
incapacitating neurologic disease.3 To the best of the
authors' knowledge, there is very limited data and
available literature on WD from Pakistan,4 so a crosssectional study was done at The Aga Khan University
Hospital, Karachi. After data collection and analysis, a
comparison with studies from India, Japan and Europe
was made.5-7

A total of 47 patients were seen from 1985 to 2011, and
32 (68.1%) among them were male. The mean age of
the patients was 26.6 ± 9.97 years. The most common
presentation in this group of patients was hepatic,
(n = 22, 46.8%), followed by neurological, (n = 17,
36.2%) and psychiatric (n = 8, 17%) patients. The
patients with psychiatric symptoms had an earlier onset
of disease at the mean age of 18.8 ± 3.3 years.
The clinical diagnosis of WD was confirmed with
ceruloplasmin level, 24-hour-urinary copper and serum
copper level (Table I). The two ratios (SGOT/SGPT,
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Table I: Diagnostic investigations for WD.
1Ceruloplasmin
224-hr

levels (g/dl)

urinary copper secretion* (ug/day)

3Serum

copper (ug/dl)*

AST/ALT ratio

Alkaline phosphatase/ total bilirubin ratio*

0.17 ± 0.13

155 (IQR 44.26; 407.75)

55.60 (IQR 34.42; 73.75)

1.92 ± 1.36

79.30 (IQR 35.05; 166.50)

* Median with interquartile ranges (IQR) has been reported for these variables
1. normal values > 0.25g/dl, 2. normal values (70-160µg/dl) 3. Normal values 70-160µg/dl

Alk.P/T.Bil) which had been recently reported in a study
in acute liver failure patients were also calculated. The
mean value for AST/ALT ratio was 1.92 ± 1.36 and
median value for Alk.P/T.Bil ratio was 79 (IQR 35.05;
166.50). MRI was done in 21 (84%) patients of
neuropsychiatric group and 17 (81%) of these were
found to have abnormal signaling within basal ganglia,
consistent with WD.

The mean age at onset was slightly higher in this cohort
as compared to other comparison studies. There was a
higher burden of WD in male population, which is quite
comparable with studies from India and Japan, but
European study on the other hand had shown a higher
female predominance (Table II). The most common
mode of presentation in this cohort was hepatic, which is
consistent with Japanese and European studies.5,7
Data from Indian study, however, has reported a high
predominance of neuropsychiatric symptoms and a
lower mean age-of-onset.6 This has also been observed
in the present study that psychiatric mode of
presentation was more common in younger age group
with a mean age of presentation at 18.8 ± 3 years.
The diagnostic biochemical parameters in this study
showed low ceruloplasmin levels in most of our patients.
For those tested for 24-hr-urinary copper, less than half
had raised levels. This is comparable with results from
Japanese study, but on the contrary, studies from India
and Europe had shown very high percentage of patients
with raised 24-hr-urinary Cu levels. Similar trends were
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Table II: Comparison of WD in Pakistan, India, Japan and European countries.
Year

Pakistan

India (6)

Japan (7)

European countries (5)

1985-2011

1970-2000

1999-2007

2000-2005

2011

Study period

Place of study

Karachi, Pakistan

Number of cases

47

Prevalence of males

68%

Male: Female

32:15

Mean age at onset (years)
Hepatic

22 (46.8%)

Neurological

17 (36.2%)

Psychiatric

Other (i-e musculoskeletal,
hemolytic or mixed symptoms)

Diagnostic tests

Ceruloplasmin levels
Serum copper

In hepatic form

In neurological form

Bangalore, India
282

196:86

Central Japan

163

66.6%

39.8%

17.5

42 (14.9%)

Heidelberg, Germany

30

20:10

69%

22 (73.3%)

65:98
17.4

96 (58.9%)

5 (16.7%)

55 (33.7%)

38 (13.55%)

3 (10%)

12 (7.4%)

Reduced in 86.6%

Reduced in 88%

-

Reduced in 88.2%

Raised in 47.6%

Raised in 96%

Raised in 36.4% with
hepatic form and 40%
with neurological form

Present in 28.6%

Present in 13.6%

8 (17%)

Present in 87.5%

7 (2.48%)

Present in 100%

seen in ophthalmological examination with KF rings,
which were present in almost all patients with neurological symptoms in all studies. However, the presence
of KF rings in patients with predominantly hepatic
symptoms varied in these studies.8

WD should be suspected in patients who have unexplained abnormal liver function tests and whose family
history is positive for liver disease. Due to similar
patterns of biochemical parameters in WD in all these
different regions and due to high percentage of hepatic
presentation in our country, a clinician should check for
atleast three values in case of unexplained liver disease;
namely (i) low ceruloplasminemia (ii) high 24-hr-urinary
copper (iii) presence of KF rings on ophthalmic
examination.
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